SpringWorks Therapeutics debuts IPO
Stamford, Connecticut-based SpringWorks Therapeutics Inc, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, has raised $162 million for its IPO after pricing its 9 million shares at $18 per share. The stock began trading September 13, 2019 on the NASDAQ under the ticker symbol "SWTX." J.P. Morgan Securities LLC, Goldman Sachs and Cowen and Company LLC are the lead underwriters. SpringWorks' pre-IPO backers include Perceptive Advisors, Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer and LifeArc.
13 September 2019•3 mins read
